All In Biotech

Drug Trial Radar · NCT07790562

A Study of Ferric Derisomaltose Injection in Chinese Participants With Iron Deficiency Anemia Under Fasting Conditions

A Randomized, Open-label, Parallel, Two-formulation, Single-dose Bioequivalence Study of Ferric Derisomaltose Injection in Chinese Participants With Iron Deficiency Anemia Under Fasting Conditions

Last checked: Nov 19, 2026Latest source record: Nov 19, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruiting

Status

Active, not recruiting

Enrollment

88

Planned (sponsor's estimate)

Start

Jul 23, 2026

Primary completion

Sep 29, 2026

Study completion Jan 2027

Sponsor

Sponsor type
Industry
Collaborators
Suzhou Chenyan Life Science Co., Ltd.; Boji Data Technology (Beijing) Co., Ltd.; Boji Medical Technology Co., Ltd.; Hopeshine-Minsheng Hospital of Xinzheng
First posted
Aug 27, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The goal of this clinical trial is to compare the pharmacokinetic profile of the developed drug product and reference product in participants with iron deficiency anemia under fasting condition. The main questions it aims to answer are: * \[Question 1\] Is there significant difference in the pharmacokinetic profile between the ferric derisomaltose injection 10mL:1000mg \[calculated by iron\]) provided by Sichuan Huiyu Pharmaceutical Co., Ltd. and the ferric derisomaltose injection held by Pharmacosmos A/S . (trade name: MonoFer®, strength: 10mL:1000mg \[calculated by iron\]) )? * \[Question 2\] Is it safe for participants with iron deficiency anemia to take ferric derisomaltose injection (10mL:1000mg \[calculated by iron\])) provided by Sichuan Huiyu Pharmaceutical Co., Ltd. under fasting condition? Participants will be randomly divided into two groups by stratified blocked randomization, with equal number of participants with iron deficiency anemia in each group, to receive test product or reference product according to the protocol below. * Dosing on D1: Group T (Test product) Group R (Reference product) * Pharmacokinetics(PK) blood sample collection * Safety evaluation

Conditions

  • Iron Deficiency Anemia

Interventions

  • Ferric Derisomaltose InjectionDrug

    For the T group, participants will have a standardized dinner on the night before the trial, followed by a fasting period of at least 10 h before receiving the test product (T,10mL:1000mg \[calculated by iron\]) via intravenous infusion, diluted to 100 mL with 0.9% sodium chloride injection, and infused continuously for 30 min (±2 min).

  • Ferric Derisomaltose Injection [MonoFer®]Drug

    For the R group, participants will have a standardized dinner on the night before the trial, followed by a fasting period of at least 10 h before receiving the reference product (trade name: MonoFer®) (R,10mL:1000mg \[calculated by iron\]) via intravenous infusion, diluted to 100 mL with 0.9% sodium chloride injection, and infused continuously for 30 min (±2 min).

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Pharmacokinetic parameter of total iron in serum: maximum observed plasma concentration (Cmax)Time frame: -24 hour, -12 hour, and 0 hour, 10 min, 20 min, 30 min, 45 min, 1 hour, 1.25 hour, 1.5 hour, 1.75 hour, 2 hour, 3 hour, 4 hour, 6 hour, 8 hour, 10 hour, 12 hour, 24 hour, 48 hour, 72 hour, 96 hour, 144 hour, and 168 hour
  2. Pharmacokinetic parameter of total iron in serum: area under the plasma concentration-time curve from time 0 to the last measurable concentration (AUC0-t)Time frame: -24 hour, -12 hour, and 0 hour, 10 min, 20 min, 30 min, 45 min, 1 hour, 1.25 hour, 1.5 hour, 1.75 hour, 2 hour, 3 hour, 4 hour, 6 hour, 8 hour, 10 hour, 12 hour, 24 hour, 48 hour, 72 hour, 96 hour, 144 hour, and 168 hour
  3. Pharmacokinetic parameter of transferrin bound iron in serum: CmaxTime frame: -24 hour, -12 hour, and 0 hour, 10 min, 20 min, 30 min, 45 min, 1 hour, 1.25 hour, 1.5 hour, 1.75 hour, 2 hour, 3 hour, 4 hour, 6 hour, 8 hour, 10 hour, 12 hour, 24 hour, 48 hour, 72 hour, 96 hour, 144 hour, and 168 hour
  4. Pharmacokinetic parameter of transferrin bound iron in serum: AUC0-tTime frame: -24 hour, -12 hour, and 0 hour, 10 min, 20 min, 30 min, 45 min, 1 hour, 1.25 hour, 1.5 hour, 1.75 hour, 2 hour, 3 hour, 4 hour, 6 hour, 8 hour, 10 hour, 12 hour, 24 hour, 48 hour, 72 hour, 96 hour, 144 hour, and 168 hour

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Hopeshine-Minsheng Hospital of Xinzheng

    Zhengzhou, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.